Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

Recruiting now · Phase 1/Phase 2

Conditions studied: Metastatic Gastric Adenocarcinoma, Second Line, Chemotherapy

In brief

Primary Objectives * In phase 1b cohort, to determine MTD (maximum tolerated dose) of nal-IRI (ONIVYDE®) in combination with Ramucirumab (Cyramza®) and TAS-102 (LONSURF®) * In phase II cohort, to evaluate disease objective response rate (ORR) of Ramucirumab (Cyramza®), nal-IRI (ONIVYDE®) in combination with TAS-102 (LONSURF®) Secondary Objectives * To evaluate disease control rate (DCR) * To evaluate progression-free survival (PFS) * To evaluate overall survival (OS) * To assess the safety profile * To study the blood biomarkers

Key facts

Study ID

NCT05927857

Run by

National Health Research Institutes, Taiwan

People needed

45

Starts

2024-04-01

Expected to finish

2028-12-31

Last updated by the study team

2026-04-09

Who can join

Age: 20 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• histologically or cytologically confirmed metastatic gastric adenocarcinoma
• patients have received only first line of systemic therapy, including recurrence during adjuvant therapy or within 6 months after the completion of adjuvant treatment.
• ECOG(Eastern Cooperative Oncology Group) performance status 0 or 1
• patients with HER2/neu-positive tumor must be exposure to Herceptin treatment
• at least one measurable disease according to the RECIST version 1.1;
• patients are aged 20 to 80 years;
• patients have a life expectancy ≥ 3 months;
• patients have adequate renal function with defined as serum creatinine ≤ 1.5 times the upper limit of normal (ULN) or Ccr ≥ 40 mL/min;
• patients with adequate hepatic function as defined by a total bilirubin ≤1.5 times the ULN, and aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 times the ULN or 5 times the ULN in the setting of liver metastases.
• patients have adequate bone marrow function, defined as an absolute neutrophil count ≥ 1500/mm3, hemoglobin ≥9 g/dL, and platelet count ≥ 100,000/mm3 (transfusion or G-CSF support before enrollment is allowed)
• patients have International Normalized Ratio (INR) ≤1.5 and a partial thromboplastin time (PTT) (PTT/aPTT) < 1.5 x ULN;
• patients' urinary protein is ≤1+ on dipstick or routine urinalysis or a 24-hour urine collection for protein must demonstrate <1000 mg of protein if urine dipstick or routine analysis is ≥ 2+;
• patients with childbearing potential shall have effective contraception for both the patient and his or her partner during the study;
• female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to first dose of protocol therapy;
• the ability to understand and willingness and to sign a written informed consent document.

You may not qualify if…

• patient can't take oral drugs;
• known hypersensitivity to irinotecan, fluoropyrimidine, or ramucirumab;
• receipt of surgery within the past 4 weeks before study enrollment;
• ≥ grade 2 diarrhea and ascites
• concurrent severe infection with intravenous systemic antibiotics treatment;
• patients have experienced any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, within 6 months prior to first dose of protocol therapy;
• patients have a prior history of GI perforation/fistula (within 6 months of first dose of protocol therapy) or risk factors for perforation;
• patients have:
• cirrhosis at a level of Child-Pugh B (or worse) or
• cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis;
• patients have a serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to first dose of protocol therapy;
• patients have undergone major surgery within 28 days prior to first dose of protocol therapy, or minor surgery/subcutaneous venous access device placement within 7 days prior to the first dose of protocol therapy. Patients have elective or planned major surgery to be performed during the course of the clinical trial;
• patients have uncontrolled or poorly-controlled hypertension (>160 mmHg systolic or > 100 mmHg diastolic for >4 weeks) despite standard medical management;
• patients have experienced any grade 3-4 GI bleeding within 3 months prior to first dose of protocol therapy;
• patients have a history of deep vein thrombosis (DVT), pulmonary embolism (PE), or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered "significant") during the 3 months prior to first dose of protocol therapy;
• patients are receiving chronic antiplatelet therapy, including dipyridamole or clopidogrel, or similar agents. Once-daily aspirin use (maximum dose 325 mg/day) is permitted;
• previously received prior nal-IRI (ONIVYDE®) or TAS-102 (LONSURF®) or ramucirumab therapy
• another previous malignancy diagnosed within the past 5 years except for non melanoma skin cancer or stage I cervical cancer;
• pregnant or breast feeding women.

Where it is running

• Taipei Veterans General Hospital — Taipei, Taiwan/Taipei, Taiwan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.